Sat02272021

Last updateSat, 27 Feb 2021 6pm

Back You are here: Inicio Biology & biomedicine Success stories

A more effective nanomedicine has been developed for the treatment of Fabry rare disease

This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work. The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future. The new drug improves on current treatments and helps reduce costs and improve patients' quality of life.

Read more ...

Antibodies test for Covid-19 with near 100% accuracy

A new serological test for Covid-19 with an accuracy close to 100% has been developed by researchers from the CSIC, in collaboration with the hospitals of La Princesa and La Paz. The Spanish biotechnology company Immunostep produces and commercializes the test.

Read more ...

The first nano drug for selectively fighting metastatic cells

Scientists from the IQAC-CSIC have participated in the development and essay of a molecule for fighting colon cancer metastasis. It is the first drug worldwide that blocks metastasis dissemination, which is the main cause of mortality of oncological patients. Also, the study demonstrates that the drug is less toxic and therefore reduces the adverse effects derived from conventional treatments.

Read more ...

Gut bacteria to treat depression and anxiety

CSIC researchers have patented a gut bacteria called Christensenella minuta that has therapeutic applications to treat mood disorders, such as depression and anxiety. This technology has been developed by a team at the Institute of Agrochemistry and Food Technology (IATA-CSIC), and has has already been licensed to LNC Therapeutics, a French biotechnology company specialized in research and development of drugs in the area of ​​the intestinal microbiome.

Read more ...

A spin-off company to design and develop preclinical assays of liver diseases

Barcelona Liver Bioservices (BLB) is a spin-off  of the CSIC and IDIBAPS created to offer services of designing and developing pre-clinical assays of liver diseases and liver toxicity of compounds.

Read more ...